BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baljevic M, Orlowski RZ. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism & Toxicology 2019;15:459-73. [DOI: 10.1080/17425255.2019.1621839] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Sloot W, Glaser N, Hansen A, Hellmann J, Jaeckel S, Johannes S, Knippel A, Lai V, Onidi M. Improved nonclinical safety profile of a novel, highly selective inhibitor of the immunoproteasome subunit LMP7 (M3258). Toxicol Appl Pharmacol 2021;429:115695. [PMID: 34419493 DOI: 10.1016/j.taap.2021.115695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Reboud-Ravaux M. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target]. Biol Aujourdhui 2021;215:1-23. [PMID: 34397372 DOI: 10.1051/jbio/2021005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mo CC, Jagannath S, Chari A, Nooka AK, Lonial S, Siegel D, Biran N, Gasparetto C, Bahlis NJ, Richardson P. Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Rev Hematol 2021;14:697-706. [PMID: 33985401 DOI: 10.1080/17474086.2021.1923473] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Fogli S, Galimberti S, Gori V, Del Re M, Danesi R. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacol Res 2021;167:105537. [PMID: 33684510 DOI: 10.1016/j.phrs.2021.105537] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Antao AM, Tyagi A, Kim KS, Ramakrishna S. Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers (Basel) 2020;12:E1579. [PMID: 32549302 DOI: 10.3390/cancers12061579] [Cited by in Crossref: 18] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
6 Kaur P, Lello LS, Utt A, Dutta SK, Merits A, Chu JJH. Bortezomib inhibits chikungunya virus replication by interfering with viral protein synthesis. PLoS Negl Trop Dis 2020;14:e0008336. [PMID: 32469886 DOI: 10.1371/journal.pntd.0008336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther 2020;5:11. [PMID: 32296023 DOI: 10.1038/s41392-020-0107-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 139] [Article Influence: 27.0] [Reference Citation Analysis]
8 Kwon D, Kim SM, Correia MA. Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications. Acta Pharm Sin B 2020;10:42-60. [PMID: 31993306 DOI: 10.1016/j.apsb.2019.11.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
9 Yang X, Zhao X, Wang X. Compound kushen injection for multiple myeloma: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e18257. [PMID: 31852094 DOI: 10.1097/MD.0000000000018257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]